title: The heart in sepsis: from basic mechanisms to clinical management.
abstract: Septic shock is characterized by circulatory compromise, microcirculatory alterations and mitochondrial damage, which all reduce cellular energy production. In order to reduce the risk of major cell death and a diminished likelihood of recovery, adaptive changes appear to be activated. As a result, cells and organs may survive in a non-functioning hibernation-like condition. Sepsis-induced cardiac dysfunction may represent an example of such functional shutdown. Sepsis-induced myocardial dysfunction is common, corresponds to the severity of sepsis, and is reversible in survivors. Its mechanisms include the attenuation of the adrenergic response at the cardiomyocyte level, alterations of intracellular calcium trafficking and blunted calcium sensitivity of contractile proteins. All these changes are mediated by cytokines. Treatment includes preload optimization with sufficient fluids. However, excessive volume loading is harmful. The first line vasopressor recommended at present is norepinephrine, while vasopressin can be started as a salvage therapy for those not responding to catecholamines. During early sepsis, cardiac output can be increased by dobutamine. While early administration of catecholamines might be necessary to restore adequate organ perfusion, prolonged administration might be harmful. Novel therapies for sepsis-induced cardiac dysfunction are discussed in this article. Cardiac inotropy can be increased by levosimendan, istaroxime or omecamtiv mecarbil without greatly increasing cellular oxygen demands. Heart rate reduction with ivabradine reduces myocardial oxygen expenditure and ameliorates diastolic filling. Beta-blockers additionally reduce local and systemic inflammation. Advances may also come from metabolic interventions such as pyruvate, succinate or high dose insulin substitutions. All these potentially advantageous concepts require rigorous testing before implementation in routine clinical practice.
authors.affiliation: Cardiosurgical Intensive Care Unit, Institute of Anesthesiology, University Hospital Zurich, Raemistrasse 100, Zurich, Switzerland. alain.rudiger@usz.ch
authors.forename: Alain
authors.initials: A
authors.lastname: Rudiger
authors.forename: Mervyn
authors.initials: M
authors.lastname: Singer
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D009202:Cardiomyopathies / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology*; D019468:Disease Management; D006801:Humans; D008833:Microcirculation / Q000187:drug effects / Q000502:physiology; D018805:Sepsis / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology*
chemical_list: D000319:Adrenergic beta-Antagonists